Common hormone therapies include: HER2-Positive Breast Cancer: Drugs like trastuzumab (Herceptin) and pertuzumab (Perjeta) target the HER2 protein, which promotes cancer cell growth. CDK4/6 Inhibitors ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Breast cancer has been a formidable health challenge ... The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin ...

Kisqali (ribociclib) given alongside endocrine therapy as adjuvant therapy for patients with stage 2 or 3 hormone receptor-positive, HER2-negative breast cancer reduced patients’ risk for ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Relay Therapeutics (RLAY – Research Report), retaining the price ...

NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

University of Kentucky Markey Cancer Center researchers identified a protein that could be key to developing new treatments ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in ...

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

An FDA panel on Thursday endorsed a cryoablation system as an alternative to surgery for some early breast cancer patients.